JP2012504602A5 - - Google Patents

Download PDF

Info

Publication number
JP2012504602A5
JP2012504602A5 JP2011530033A JP2011530033A JP2012504602A5 JP 2012504602 A5 JP2012504602 A5 JP 2012504602A5 JP 2011530033 A JP2011530033 A JP 2011530033A JP 2011530033 A JP2011530033 A JP 2011530033A JP 2012504602 A5 JP2012504602 A5 JP 2012504602A5
Authority
JP
Japan
Prior art keywords
antibody
hcv
epitope
cell line
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011530033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504602A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078884 external-priority patent/WO2010039154A1/en
Publication of JP2012504602A publication Critical patent/JP2012504602A/ja
Publication of JP2012504602A5 publication Critical patent/JP2012504602A5/ja
Withdrawn legal-status Critical Current

Links

JP2011530033A 2008-10-05 2008-10-05 Ｃ型肝炎抗体およびその使用 Withdrawn JP2012504602A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2012504602A JP2012504602A (ja) 2012-02-23
JP2012504602A5 true JP2012504602A5 (2) 2012-11-01

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530033A Withdrawn JP2012504602A (ja) 2008-10-05 2008-10-05 Ｃ型肝炎抗体およびその使用

Country Status (12)

Country Link
US (1) US8858947B2 (2)
EP (1) EP2331573A4 (2)
JP (1) JP2012504602A (2)
KR (1) KR20110061624A (2)
CN (1) CN102197050A (2)
AU (1) AU2008362482A1 (2)
BR (1) BRPI0823197A2 (2)
CA (1) CA2738644A1 (2)
EA (1) EA201170353A1 (2)
IL (1) IL212040A0 (2)
MX (1) MX2011003613A (2)
WO (1) WO2010039154A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052735A1 (ja) * 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
CN103649316B (zh) 2011-05-02 2017-07-28 约翰霍普金斯大学 合成的丙型肝炎基因组和制备及使用方法
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
EP4509180A3 (en) * 2016-03-22 2025-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
CN107011435B (zh) 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
WO2000026418A1 (en) * 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS

Similar Documents

Publication Publication Date Title
JP2012504602A5 (2)
CN111606993B (zh) 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
JP2009537143A5 (2)
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
JP2018135370A (ja) 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
JP2010100624A5 (2)
JP4287280B2 (ja) ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
JP2010501594A5 (2)
JP2017113019A5 (2)
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
Ji et al. Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti‐CD81 monoclonal antibody
CA3181026A1 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN113354731B (zh) 冠状病毒的人源单克隆抗体及其应用
TWI511977B (zh) 抗登革熱病毒非結構性蛋白１之單株抗體及其用途
Yu et al. Potent anti‐SARS‐CoV‐2 efficacy of COVID‐19 hyperimmune globulin from vaccine‐immunized plasma
Wang et al. A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy
CN106749644B (zh) 一种全人源抗hcv的中和抗体-trn1001
CN1545551B (zh) 针对丙型肝炎病毒e2糖蛋白的人单克隆抗体
JP2004533991A5 (2)
CN101851274B (zh) 抑制丙型肝炎病毒侵入的多肽
JP2011529882A5 (2)
JP2006504645A5 (2)
AU2001282425A1 (en) Human monoclonal antibody against hepatitis C virus E2 glycoprotein
JP2014012683A5 (2)
Xu et al. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS–CoV F (ab′) 2 in macaque